Generic semi-automated radiofluorination strategy for single domain antibodies: [
Automation
Biomolecules
Fluorine-18
Single domain antibodies
Journal
EJNMMI radiopharmacy and chemistry
ISSN: 2365-421X
Titre abrégé: EJNMMI Radiopharm Chem
Pays: England
ID NLM: 101714628
Informations de publication
Date de publication:
24 Jul 2024
24 Jul 2024
Historique:
received:
12
06
2024
accepted:
15
07
2024
medline:
26
7
2024
pubmed:
26
7
2024
entrez:
24
7
2024
Statut:
epublish
Résumé
Radiofluorination of single domain antibodies (sdAbs) via N-succinimidyl-4-[ [ [
Sections du résumé
BACKGROUND
BACKGROUND
Radiofluorination of single domain antibodies (sdAbs) via N-succinimidyl-4-[
RESULTS
RESULTS
[
CONCLUSION
CONCLUSIONS
[
Identifiants
pubmed: 39048805
doi: 10.1186/s41181-024-00286-8
pii: 10.1186/s41181-024-00286-8
doi:
Types de publication
Journal Article
Langues
eng
Pagination
54Subventions
Organisme : Fonds Wetenschappelijk Onderzoek
ID : I001618N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : I005622N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1S06622N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1230824N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 1801619N
Organisme : Fonds Wetenschappelijk Onderzoek
ID : 12H3619N
Organisme : Vrije Universiteit Brussel
ID : SRP50
Organisme : Vrije Universiteit Brussel
ID : SRP95
Organisme : Vrije Universiteit Brussel
ID : SRP62
Organisme : Vrije Universiteit Brussel
ID : IOF3018
Organisme : Vrije Universiteit Brussel
ID : IOF3009
Organisme : Innoviris
ID : 2020-RDIR-1
Informations de copyright
© 2024. The Author(s).
Références
Ackermann U, Yeoh SD, Sachinidis JI, Poniger SS, Scott AM, Tochon-Danguy HJ. A simplified protocol for the automated production of succinimidyl 4-[18F]fluorobenzoate on an IBA Synthera module. J Labell Comp Radiopharm. 2011;54:671–3.
doi: 10.1002/jlcr.1892
Backhaus P, Gierse F, Burg MC, Büther F, Asmus I, Dorten P, et al. Translational imaging of the fibroblast activation protein (FAP) using the new ligand [
pubmed: 34957527
doi: 10.1007/s00259-021-05653-0
Bala G, Blykers A, Xavier C, Descamps B, Broisat A, Ghezzi C, et al. Targeting of vascular cell adhesion molecule-1 by
pubmed: 26800768
doi: 10.1093/ehjci/jev346
Bala G, Crauwels M, Blykers A, Remory I, Marschall ALJ, Dübel S, et al. Radiometal-labeled anti-VCAM-1 nanobodies as molecular tracers for atherosclerosis—impact of radiochemistry on pharmacokinetics. Biol Chem. 2019;400:323–32.
pubmed: 30240352
doi: 10.1515/hsz-2018-0330
Blykers A, Schoonooghe S, Xavier C, D’Hoe K, Laoui D, D’Huyvetter M, et al. PET imaging of macrophage mannose receptor-expressing macrophages in tumor stroma using
pubmed: 26069306
doi: 10.2967/jnumed.115.156828
Boss SD, Ametamey SM. Development of folate receptor−targeted PET radiopharmaceuticals for tumor imaging—a bench-to-bedside journey. Cancers. 2020;12(12):1508.
pubmed: 32527010
pmcid: 7352234
doi: 10.3390/cancers12061508
Broisat A, Hernot S, Toczek J, De Vos J, Riou LM, Martin S, et al. Nanobodies targeting mouse/human VCAM1 for the nuclear imaging of atherosclerotic lesions. Circ Res. 2012;110:927–37.
pubmed: 22461363
pmcid: 3918224
doi: 10.1161/CIRCRESAHA.112.265140
Chung K-M, Hsu S-C, Chu Y-R, Lin M-Y, Jiaang W-T, Chen R-H, et al. Fibroblast activation protein (FAP) is essential for the migration of bone marrow mesenchymal stem cells through RhoA activation. PLoS ONE. 2014;9:e88772.
pubmed: 24551161
pmcid: 3923824
doi: 10.1371/journal.pone.0088772
Cleeren F, Lecina J, Bridoux J, Devoogdt N, Tshibangu T, Xavier C, et al. Direct fluorine-18 labeling of heat-sensitive biomolecules for positron emission tomography imaging using the Al
pubmed: 30250289
doi: 10.1038/s41596-018-0040-7
Davis RA, Drake C, Ippisch RC, Moore M, Sutcliffe JL. Fully automated peptide radiolabeling from [18 F]fluoride. RSC Adv. 2019;9:8638–49.
pubmed: 35518701
pmcid: 9061836
doi: 10.1039/C8RA10541C
De Pauw T, De Mey L, Debacker JM, Raes G, Van Ginderachter JA, De Groof TWM, et al. Current status and future expectations of nanobodies in oncology trials. Expert Opin Investig Drugs. 2023;32:705–21.
pubmed: 37638538
doi: 10.1080/13543784.2023.2249814
Dekempeneer Y, Massa S, Santens F, Navarro L, Berdal M, Lucero MM, et al. Preclinical evaluation of a radiotheranostic single-domain antibody against fibroblast activation protein α. J Nucl Med. 2023;64:1941–8.
pubmed: 38040444
doi: 10.2967/jnumed.123.266381
D’Huyvetter M, De VJ, Caveliers V, Vaneycken I, Heemskerk J, Duhoux FP, et al. Phase I trial of
pubmed: 33277400
doi: 10.2967/jnumed.120.255679
Di Gialleonardo V, Signore A, Glaudemans AWJM, Dierckx RAJO, De Vries EFJ. N-(4–
pubmed: 22499614
doi: 10.2967/jnumed.111.091306
Fitzgerald AA, Weiner LM. The role of fibroblast activation protein in health and malignancy. Cancer Metastasis Rev. 2020;39:783–803.
pubmed: 32601975
pmcid: 7487063
doi: 10.1007/s10555-020-09909-3
Fujimoto H, Fujita N, Hamamatsu K, Murakami T, Nakamoto Y, Saga T, et al. First-in-human evaluation of positron emission tomography/computed tomography with [
pubmed: 34489868
doi: 10.3389/fendo.2021.717101
Giesel FL, Adeberg S, Syed M, Lindner T, Jiménez-Franco LD, Mavriopoulou E, et al. FAPI-74 PET/CT using either
pubmed: 32591493
pmcid: 8679591
doi: 10.2967/jnumed.120.245084
Gnesin S, Müller J, Burger IA, Meisel A, Siano M, Früh M, et al. Radiation dosimetry of
pubmed: 32270313
pmcid: 7142191
doi: 10.1186/s13550-020-00624-2
Gondry O, Xavier C, Raes L, Heemskerk J, Devoogdt N, Everaert H, et al. Phase I study of [
pubmed: 37474271
pmcid: 10478821
doi: 10.2967/jnumed.122.264853
Gondry O, Caveliers V, Xavier C, Raes L, Vanhoeij M, Verfaillie G, et al. Phase II trial assessing the repeatability and tumor uptake of [
pubmed: 38302159
pmcid: 10858381
doi: 10.2967/jnumed.123.266254
Guzik P, Fang HY, Deberle LM, Benešová M, Cohrs S, Boss SD, et al. Identification of a PET radiotracer for imaging of the folate receptor-α: a potential tool to select patients for targeted tumor therapy. J Nucl Med. 2021;62:1475–81.
pubmed: 33452043
pmcid: 8724891
doi: 10.2967/jnumed.120.255760
Harada H, Gonzalez T, Muminovic M, Nano O, Vulfovich M. Folate receptor alpha—a novel approach to cancer therapy. Int J Mol Sci. 2024;25(25):1046.
Herzog TJ, Pignata S, Ghamande SA, Rubio MJ, Fujiwara K, Vulsteke C, et al. Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer. Gynecol Oncol. 2023;170:300–8.
pubmed: 36758420
doi: 10.1016/j.ygyno.2023.01.003
Jacobson O, Kiesewetter DO, Chen X. Fluorine-18 radiochemistry, labeling strategies and synthetic routes. Bioconjug Chem. 2015;26:1–18.
pubmed: 25473848
doi: 10.1021/bc500475e
Keane FM, Yao TW, Seelk S, Gall MG, Chowdhury S, Poplawski SE, et al. Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs. FEBS Open Bio. 2014;4:43–54.
doi: 10.1016/j.fob.2013.12.001
Keyaerts M, Xavier C, Heemskerk J, Devoogdt N, Everaert H, Ackaert C, et al. Phase I study of
pubmed: 26449837
doi: 10.2967/jnumed.115.162024
Kim HK, Javed MR, Chen S, Zettlitz KA, Collins J, Wu AM, et al. On-demand radiosynthesis of: N -succinimidyl-4-[
pubmed: 35530758
pmcid: 9072849
doi: 10.1039/C9RA06158D
Lemaire M, D’Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E, De Bruyne E, et al. Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic nanobodies. Leukemia. 2014;28:444–7.
pubmed: 24166214
doi: 10.1038/leu.2013.292
Li J, Chen K, Liu H, Cheng K, Yang M, Zhang J, et al. An activatable near infrared fluorescent probe for in vivo imaging of fibroblast activation protein-alpha. Bioconjug Chem. 2012;23:1704.
pubmed: 22812530
pmcid: 3419799
doi: 10.1021/bc300278r
Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of
pubmed: 31836685
pmcid: 7413240
doi: 10.2967/jnumed.119.236786
Millul J, Bassi G, Mock J, Elsayed A, Pellegrino C, Zana A, et al. An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications. Proc Natl Acad Sci U S A. 2021;118:e2101852118.
pubmed: 33850024
pmcid: 8072232
doi: 10.1073/pnas.2101852118
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, et al. Mirvetuximab soravtansine in FRα-positive, platinum-resistant ovarian cancer. N Engl J Med. 2023;389:2162–74.
pubmed: 38055253
doi: 10.1056/NEJMoa2309169
Nagachinta S, Novelli P, Joyard Y, Maindron N, Riss P, Dammicco S. Fully automated
doi: 10.1038/s41598-022-23552-8
Nikolaidis A, Moschakis T. On the reversibility of ethanol-induced whey protein denaturation. Food Hydrocoll. 2018;84:389–95.
doi: 10.1016/j.foodhyd.2018.05.051
Nikolaidis A, Andreadis M, Moschakis T. Effect of heat, pH, ultrasonication and ethanol on the denaturation of whey protein isolate using a newly developed approach in the analysis of difference-UV spectra. Food Chem. 2017;232:425–33.
pubmed: 28490093
doi: 10.1016/j.foodchem.2017.04.022
Parker N, Turk MJ, Westrick E, Lewis JD, Low PS, Leamon CP. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem. 2005;338:284–93.
pubmed: 15745749
doi: 10.1016/j.ab.2004.12.026
Poplawski SE, Hallett RM, Dornan MH, Novakowski KE, Pan S, Belanger AP, et al. Preclinical development of PNT6555, a boronic acid-based, fibroblast activation protein-α (FAP)–targeted radiotheranostic for imaging and treatment of FAP-positive tumors. J Nucl Med. 2023;65:100–8.
doi: 10.2967/jnumed.123.266345
Scaranti M, Cojocaru E, Banerjee S, Banerji U. Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 2020;17:349–59.
pubmed: 32152484
doi: 10.1038/s41571-020-0339-5
Scott PJH, Shao X. Fully automated, high yielding production of N-succinimidyl 4-[
doi: 10.1002/jlcr.1785
Sega EI, Low PS. Tumor detection using folate receptor-targeted imaging agents. Cancer Metastasis Rev. 2008;27:655–64.
pubmed: 18523731
doi: 10.1007/s10555-008-9155-6
Tang G, Zeng W, Yu M, Kabalka G. Facile synthesis of N-succinimidyl 4-[18F]fluorobenzoate ([18F]SFB) for protein labeling. J Labell Comp Radiopharm. 2008;51:68–71.
doi: 10.1002/jlcr.1481
Tang G, Tang X, Wang X. A facile automated synthesis of N-succinimidyl 4-[
doi: 10.1002/jlcr.1758
Thonon D, Goblet D, Goukens E, Kaisin G, Paris J, Aerts J, et al. Fully automated preparation and conjugation of N-Succinimidyl 4-[
pubmed: 21267662
doi: 10.1007/s11307-011-0470-x
Toyohara J, Al-Qahtani M, Huang Y-Y, Cazzola E, Todde S, Furumoto S, et al. Highlight selection of radiochemistry and radiopharmacy developments by editorial board. EJNMMI Radiopharm Chem. 2022;7:25.
pubmed: 36182995
pmcid: 9526771
doi: 10.1186/s41181-022-00177-w
Vaidyanathan G, Zalutsky MR. Synthesis of N-succinimidyl 4-[
pubmed: 17487148
doi: 10.1038/nprot.2006.264
Verweij NJF, Yaqub M, Bruijnen STG, Pieplenbosch S, ter Wee MM, Jansen G, et al. First in man study of [
pubmed: 31974480
pmcid: 6978456
doi: 10.1038/s41598-020-57841-x
Wang S, Zhou X, Xu X, Ding J, Liu T, Jiang J, et al. Dynamic PET/CT imaging of
pubmed: 33777814
pmcid: 7991833
doi: 10.3389/fonc.2021.651005
Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, et al. 68Ga-FAPI-04 Versus
pubmed: 34249748
pmcid: 8267923
doi: 10.3389/fonc.2021.693640
Wei W, Rosenkrans ZT, Liu J, Huang G, Luo Q-Y, Cai W. ImmunoPET: concept, design, and applications. Chem Rev. 2020;120:3787–851.
pubmed: 32202104
pmcid: 7265988
doi: 10.1021/acs.chemrev.9b00738
Xavier C, Blykers A, Vaneycken I, D’Huyvetter M, Heemskerk J, Lahoutte T, et al.
pubmed: 27067045
doi: 10.1016/j.nucmedbio.2016.01.002
Xavier C, Blykers A, Laoui D, Bolli E, Vaneyken I, Bridoux J, et al. Clinical translation of [
pubmed: 30671739
doi: 10.1007/s11307-018-01302-5
Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651–67.
pubmed: 35608703
pmcid: 9399058
doi: 10.1007/s00259-022-05842-5
Zhao L, Niu B, Fang J, Pang Y, Li S, Xie C, et al. Synthesis, preclinical evaluation, and a pilot clinical pet imaging study of
pubmed: 34556528
pmcid: 9157726
doi: 10.2967/jnumed.121.263016
Vynfinit | European Medicines Agency [Internet]. [cited 2024 Jan 29]. https://www.ema.europa.eu/en/medicines/human/EPAR/vynfinit